Is PT-141 (Bremelanotide) Legal in Florida? How to Access It Legally
HealthRX.com
Bremelanotide is legal in Florida only as Vyleesi
See the public record for Bremelanotide
At a glance
- Federal status / Prescription-only; FDA-approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Approved form / 1.75 mg subcutaneous autoinjector [1]
- Not indicated for / Postmenopausal women, men, or enhancing sexual performance [1]
- Boxed warning / None, and no REMS [1][2]
- Compounded or research-use PT-141 / Not Vyleesi; not FDA-approved drugs [1][3]
- Florida pharmacy law / Chapter 465 is the state's Pharmacy chapter [4]
What is bremelanotide's federal status?
FDA approved bremelanotide as Vyleesi on June 21, 2019 (NDA 210557) [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector pen, available by prescription only. It has no boxed warning, and no risk evaluation and mitigation strategy (REMS) appears in the label or the 2019 approval letter [1][2].
What does the approval cover?
Premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a coexisting medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for postmenopausal women or in men, and not to enhance sexual performance [1]. Dosing is 1.75 mg subcutaneously into the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity; the label says not to use more than one dose within 24 hours and does not recommend more than eight doses per month [1].
Is compounded or research-use PT-141 the same product?
No. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1]. Bremelanotide is not on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5][6][7]. Neither point makes a compounded product FDA-approved.
What about Florida law?
In Florida, as elsewhere, the FDA-approved bremelanotide product is prescription-only Vyleesi [1][2]. Chapter 465 of the Florida Statutes is the state's Pharmacy chapter; its section list covers pharmacy licensure, permits, and the filling and dispensing of prescriptions, and it does not mention bremelanotide [4].
Questions worth asking
What does the label say to expect?
Nausea was reported by 40.0% of Vyleesi patients versus 1.3% on placebo, with 13% needing anti-nausea medicine and 8% stopping because of it [1]. Each dose transiently raises blood pressure: maximal increases were 6 mmHg systolic and 3 mmHg diastolic [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease [1].
Is Vyleesi approved for men?
No. The label says Vyleesi is not indicated for men [1]. A 2004 study evaluated intranasal PT-141 in men, but the FDA-approved product is a 1.75 mg subcutaneous autoinjector [1][8].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 (Bremelanotide) legal in Florida?
Do I need a prescription for bremelanotide?
Is compounded PT-141 the same as Vyleesi?
Who is Vyleesi approved for?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Where can I buy PT-141 peptide?
No seller or source is named. Vyleesi is prescription only, sold as a 1.75 mg subcutaneous autoinjector. Compounded and research-use PT-141 are not Vyleesi and are not FDA-approved drugs.
Is Vyleesi the same as PT-141?
Vyleesi is the FDA-approved product containing bremelanotide, approved June 21, 2019 (NDA 210557). PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug.
How long does it take for PT-141 to work?
No time to effect is stated. The label directs 1.75 mg subcutaneously into the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose within 24 hours.
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Chapter 465 - 2023 Florida Statutes - The Florida Senate.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-9.